ASAH1-mediated sphingolipid metabolic reprogramming in venetoclax resistance of AML: beyond the monocytic phenotypes
Abstract Background Venetoclax (VEN) in combination with hypomethylating agents has emerged as a pivotal therapy for elderly acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, monocytic AML exhibit greater resistance to VEN-based regimens compared to non-monocytic...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMC
2025-11-01
|
| Colección: | BMC Cancer |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1186/s12885-025-15272-9 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|